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              ”Research is what I’m doing when I don’t know what I’m doing” 
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ABSTRACT 
Membrane proteins constitute 20-30 % of the human genome and make up 60 % of all 
drug targets. They play important roles in key cellular functions such as small 
molecules transport, cell-cell interactions and cell signaling. Membrane proteins and 
proteomics have been notoriously difficult to combine. Most proteomic methods 
commonly used for analysis of soluble proteins cannot be used for membrane proteins, 
mainly due to their amphipathic nature. In this thesis, a method is described for 
quantitative proteomic analysis of membrane protein enriched samples. In paper I the 
method is applied to small cell lung cancer cell lines to elucidate Doxorubicin 
resistance mechanisms. We demonstrate that the microsomal preparation and iTRAQ 
labeling is reproducible regarding protein content and composition. The rationale using 
narrow range peptide isoelectric focusing separation is demonstrated by its ability to: i) 
lowering the complexity of the sample by two thirds while keeping a high proteome 
coverage (96%), ii) providing high separation efficiency and iii) allowing for peptide 
validation and possibly identifications of post transcriptional modifications. The work 
from paper I encouraged us to further explore the properties of narrow range peptide 
IEF as a separation strategy. We and others have shown that using IEF as the first 
dimension of separation is a highly suitable method when analyzing complex samples. 
It provides an orthogonal separation strategy to reversed phase chromatography as well 
as giving the opportunity to reduce false positives and false negatives generated in the 
database search, using the pI values of the peptides. In paper II, we wanted to explore 
the possibilities of using a combination of narrow range peptide IEF and reversed phase 
chromatography to increase the information content of a proteomic analysis. In the final 
two papers of this thesis, the method described in paper I is subsequently applied to 
clinical material. In paper III, the membrane protein fractions of benign and malignant 
adrenocortical tumors are compared. The mitochondrial membrane protein GRIM-19, a 
negative regulator of STAT3, is identified as down-regulated in the malignant tissue. 
The possible role of GRIM-19 down-regulation in the tumorigenesis is discussed. In 
paper IV, the membrane-associated protein population of alveolar macrophages 
isolated from Sarcoidosis patients is compared with healthy controls. Affected 
pathways are described and discussed. 
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1 BACKGROUND 
 
1.1 PROTEOMICS 
The genome is the entirety of an organism's hereditary information. The information is 
coded in the DNA, which consists of both coding and non-coding sequences. The 
human genome was mapped in 20011-2 and is estimated to contain approximately 
20 000 protein-coding sequences, or genes3-4. A gene is a series of nucleotides, or 
simplified, letters, and the order of these letters decide into what kind of protein the 
gene will be coded into. The proteins are the true work horses of an organism; each 
protein has specific functions within or outside the cell. A protein can have different 
functions or characteristics depending on for instance certain structural modifications or 
cellular location. Also, a gene can have alternative splicing variants and become 
differentially edited at RNA level, and consequently give rise to different proteins. This 
means that the number of human proteins greatly exceeds the number of human genes. 
The term proteome (in analogy to genome) was first introduced by Marc Wilkins in 
1994 an was subsequently published in 19955. Wilkins defined the proteome as the 
entire protein complement of a genome, a cell, a tissue or an organism. The human 
proteome has not been mapped but a single human cell has been estimated to contain 
~100 000 proteins6. 
Proteomics is the common name for the methods used to study the proteome. Several 
“omics” research areas have emerged in the years following the mapping of the human 
genome, e.g. genomics (study of the genes), transcriptomics (study of the transcripts, 
mRNAs) and metabolomics (study of the metabolites), and new omics fields regularly 
pop up. The overall aim of these technologies is that by studying several molecules at 
the same time instead of one at the time, patterns can be recognized and previously 
unknown molecules may be identified of potential interest for the question at hand. In 
an ordinary research project, the researcher usually has a hypothesis and experiments 
are then performed to prove this hypothesis. In omics research, the experiments are 
instead hypothesis driving; you go in the direction the experiments point you.  
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In a proteomic experiment, either a top-down or a bottom-up approach may be 
employed (figure 1). In a top-down approach, focus lies on separating intact proteins, 
either by two-dimensional electrophoresis (2-DE) or by mass spectrometry (MALDI-
TOF MS or SELDI-TOF MS). 2-DE7 was for long the standard method in a proteomic 
experiment. The basic principles consist of first separating the proteins by their 
isoelectric point (pI) in an immobilized pH gradient, after which the proteins are 
separated by size by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). The generated gels are then stained, the spots are excised and the proteins 
identified using mass spectrometry. On a single gel, thousand(s) of proteins can be 
visualized, however far from all of them are assigned with identities. Using mass 
spectrometry to separate intact proteins usually generates protein profiles that are 
compared between samples, and an alternative technique is then employed to identify 
the proteins. In a bottom-up approach (or shotgun approach), the proteins are first 
digested into peptides and focus lies on separating the peptides before mass 
spectrometry analyses. This approach has been used throughout the studies comprising 
this thesis and will be further presented in the coming sections. 
 
 
1.1.1 Fractionation 
The dynamics of the proteome, as opposed to the genome, makes it more challenging to 
study. Not only is it greater in number, as discussed above, but the proteome constantly 
changes by responding to environmental parameters. Proteins are also chemically more 
heterogeneous as a group than DNA or RNA; they differ largely in size, solubility and 
pI. Additionally, some proteins only exist in a few copies per cell, whereas others can 
be high-abundant; this is often referred to as the high dynamic range problem. This 
presents an analytical challenge, since mass spectrometers have limited dynamic range. 
The complex nature of a proteome sample calls for strategies to reduce the complexity 
Figure 1. Proteomic experiments can have either a bottom-up approach  (1) or a top-
down approach  (2a and 2b). 
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in order to aid identification of as many proteins as possible. To do this, the sample is 
usually fractionated and this can be done either on protein level or on peptide level or 
by using a combination of the two.  
Fractionation on a protein level can be performed either by using chemical 
characteristics of the proteins or their cellular location (section 1.2.1). Liquid 
chromatography methods can be used to separate proteins based on hydrophobicity, 
size or charge8. There are also methods targeting specific sub-groups of proteins, e.g. 
glycosylated proteins9 or high-abundant proteins10. One-dimensional gel 
electrophoresis followed by in-gel digestion of protein bands has been employed to 
separate proteins according to size11. 
When using a bottom-up approach, fractionation at peptide level is crucial since the 
complexity of the sample is further increased due to enzymatic cleavage. In analogy to 
protein separation, liquid chromatography can be used to separate peptides based on 
hydrophobicity or charge. One of the most commonly used techniques is the MudPIT 
(multidimensional protein identification technology) approach, where the peptides are 
separated both by strong anion exchange (SCX) and reversed phase (RP) 12-13. 
Isoelectric focusing is a technique that has gained increasingly more interest14-15. It can 
be performed both in-gel and in-solution16 and different pH ranges can be utilized, 
depending on the main purpose of the strategy. Usually, the peptides are first separated 
by pI after which a standard reversed phase separation is performed. Narrow range 
isoelectric focusing has been employed in all four papers included in this thesis (papers 
I-IV). In this technique, peptides are separated in an immobilized pH gradient, which 
spans a little over 1 pH unit. This way, the sample complexity is reduced by two thirds, 
while high proteome coverage is maintained (see section 2.3.6 and paper I). Reduced 
sample complexity increases the chances of identifying low-abundant proteins. Another 
advantage of using IEF as the first dimension separation is that the added information 
about the peptide pI can be used to validate the identifications. Several algorithms to 
calculate the pIs have been developed17-18; this is further explored in paper II.  
1.1.2 Mass spectrometry 
To obtain the identity of the proteins studied, mass spectrometry is by far the most 
widely used method today. The basic principle of mass spectrometry consists of 
ionizing chemical compounds to generate charged molecules or molecule fragments 
and then measuring their mass-to-charge (m/z) ratios. A mass spectrometer is built up 
by three modules; an ion source, a mass analyzer and a detector.  
 
The analytes of interest are ionized and brought to gas-phase in the ion source. There 
are different types of ion sources; the two most commonly used in proteomics are 
MALDI (matrix-assisted laser desorption/ionization) and ESI (electrospray ionization). 
MALDI19 is based on the co-crystallization of sample molecules with an energy-
absorbing matrix. When a laser beam hits the crystals, a matrix plume is formed that 
expands into the gas-phase and the sample molecules are ionized, forming 
predominately singly charged ions. In ESI20, ionization per se is not occurring but 
rather pre-existent ions are brought from solution into the gas-phase. It is a soft 
ionization technique giving rise to little or no fragmentation of the molecules. Since the 
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ESI process is starting from droplets, it is easily coupled to on-line liquid 
chromatography (LC). 
The next step takes place when the ions enter the mass analyzer. Here the ions are 
separated based on their mass-to-charge ratios. Quadrupoles are the most common type 
of mass analyzers. Briefly, it consists of four circular rods and ions are separated based 
on the stability of their trajectories in the oscillating electric fields that are applied to the 
rods. Often three quadrupoles are placed in series; the first one is used to scan across a 
preset m/z range and select an ion of interest, the second quadrupole is the collision cell 
and the third analyzes the fragment ions generated in the collision cell21-22. In the 
quadrupole ion trap analyzers, ions are introduced in a pulsing mode, as opposed to 
normal quadrupoles where they enter in a continuous mode. The ions are detained in 
the ion trap, and how stably trapped the ion will be depends on the mass-to-charge 
ratio22. A linear quadrupole ion trap (LTQ) is similar to a quadrupole ion trap, but it 
has an extended volume in the trap to increase the sensitivity. In the time-of-flight 
analyzer, ions are accelerated by an electric field of known strength where the velocity 
of the ions depends on the mass-to-charge ratio. The time that it takes for the ion to 
reach the detector is measured and this time depends on the mass-to-charge ratio; 
smaller ions travel faster23. The fourier transform ion cyclotron resonance (FTICR) 
analyzer measures mass by detecting the image current produced by ions cyclotroning 
in a magnetic field24. The ions that are affected by a magnetic field move at a given 
cyclotron frequency depending on their m/z and this is subsequently measured. By 
using Fourier transformation the frequency is converted to a mass-to-charge value. The 
Orbitrap analyzer is similar to the FTICR, with the difference that it uses an 
electrostatic field instead of a magnetic field to separate the masses25-28. A linear ion 
trap is often used as a front end of the Orbitrap (LTQ-Orbitraps), thereby combining the 
benefits of an ion trap (speed, large trapping capacity, MSn capability and versatility) 
with the benefits of an FTICR instrument (high mass accuracy, high resolving power, 
high sensitivity and high dynamic range)29.  
The last module, the detector, registers the number of ions at any given m/z value. 
Typically, some type of electron multiplier is used; the most commonly used in modern 
instruments is the microchannel plate detector30. In FTICR and Orbitrap instruments, 
the detector consists of a pair of metal surfaces within the mass analyzer/ion trap region 
which the ions only pass near as they oscillate. In all detectors, the signal is converted 
to a mass spectrum with m/z on the x-axis and ion count/intensity on the y-axis. 
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1.2 MEMBRANE PROTEINS 
Membrane proteins are part of the interface between the outside and the inside of the 
cell, as well as the interface between intracellular compartments. As such, they play 
important roles in key cellular functions such as small molecules transport, cell-cell 
interactions and cell signaling. It is estimated that approximately 20-30 % of all human 
proteins are membrane proteins31-32. The fact that ~60 % of all drug targets are directed 
towards membrane proteins reflects their importance33. 
The membranes of living cells are composed by a lipid bilayer, which serves both to 
separate different compartments of the cell and to separate the cell from the 
surrounding environment. The lipids in the membrane consist of hydrocarbon chains, 
which are hydrophobic, attached to polar phosphate head groups, which are water 
soluble. The name bilayer stems from the fact that the hydrocarbon chains of two 
monolayers of lipids are fused together to form a single sheet with the polar head 
groups on both sides. This elegant solution makes the membrane soluble, but not 
permeable.  
There are different classes of membrane proteins. A first distinction must be made 
between integral membrane proteins (IMP) and membrane-associated proteins (MAP). 
MAPs are attached to the surface of the membrane whereas the protein in itself is a 
soluble protein. IMPs on the other hand, span the lipid bilayer. The driving force 
behind IMP structure is the hydrophobic core of this bilayer. Since peptide bonds are 
highly polar, proteins must adopt secondary structures that shield the backbone from 
the lipid core. This is achieved by allowing extensive hydrogen bonding between 
backbone amides and carbonyls. IMPs are further divided into α-helical bundle 
proteins and β-barrel proteins.     
β-Barrel proteins mainly exist in the outer membranes of Gram-negative bacteria, 
chloroplasts and mitochondria, where they regulate membrane integrity and allow for 
passive influx/efflux of small molecules34. The membrane-spanning segments consist 
of β-strands organized in a barrel where the interior forms a pore with a polar 
environment. β-Barrel proteins have an overall hydropathy that is similar to soluble 
proteins35.  
α-Helical bundle proteins are abundant and found in all membrane types, except for the 
outer membrane of Gram-negative bacteria. These proteins are built up from α-helices 
that span the lipid bilayer, connected by loop regions that extend into the cyto- or 
periplasm. They can be divided into bitopic proteins (figure 2a), which have one 
transmembrane domain (TMD) or polytopic (figure 2b), which have multiple TMDs. 
Bitopic proteins are often cell surface markers, receptors or adhesion factors. The 7-
TMD GPCRs (G-protein coupled receptors) make out a large part of the polytopic 
proteins in mammals. α-Helical bundle proteins have been the focus in the experiments 
in this thesis, and will hereafter simply be referred to as membrane proteins. 
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1.2.1 Enrichment strategies 
The most straightforward approach to fractionate the proteome involves cell lysis 
followed by sequential centrifugation steps to remove cell debris and isolate the 
membrane from the soluble protein fraction36. Further purification can be accomplished 
by subcellular fractionation, a concept that was pioneered by De Duve and colleagues 
in 1955 using rat liver tissue37. The procedure involves cell disruption, aiming at 
maintaining structural and functional integrity of the intracellular organelles, followed 
by a series of centrifugation steps to separate different populations of cellular 
compartments or organelles based on their mass and/or density38. One of the most 
widely used techniques for subcellular fractionation is density gradient centrifugation39-
40, using e.g. sucrose, sorbitol, Ficoll™ or Percoll™. Here different membranes 
partition into different fractions depending on the density of the membrane. This 
technique has been used to isolate numerous subcellular structures; e.g. plasma 
membranes41, mitochondria42, Golgi43, synaptic vesicles44 and platelet membranes45. 
Other techniques for subcellular fractionation include free-flow electrophoresis46 and 
immunoaffinity purification44.   
The plasma membrane has gained much attention, being the physical barrier between a 
eukaryotic cell and its environment. Plasma membrane proteins carry out many 
important biological functions like intercellular communication and signal transduction. 
Therefore, efforts have been made to isolate only the plasma membrane, with as little 
contamination from other membranes as possible. Jacobson and colleagues developed a 
method where they coated cells with colloidal silica, after which the silica-membrane 
complexes were cross-linked using an anionic polymer47. After cell lysis, the plasma 
membrane sheets could be readily isolated by centrifugation owing to their increased 
density. The method has been applied to cells48-49 as well as tissue50-51. Another method 
for isolation of the plasma membrane is aqueous-polymer two-phase partitioning52. 
Here, two structurally distinct water-soluble polymers are mixed in an aqueous solution 
and above a critical concentration the polymers will separate into two distinct phases, 
Figure 2. a) Bitopic integral membrane protein. b) Polytopic integral 
membrane protein. 
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with plasma membranes preferentially segregating into the more hydrophobic phase. 
Common polymers used in this method are polyethylene glycol (PEG) and dextran. 
1.2.1.1 Enriching for integral membrane proteins 
To further enrich for integral membrane proteins, there are different strategies for 
removal of membrane-associated proteins (MAPs) and lipids, the two most common 
“contaminators”. MAPs can be quite readily removed from the membrane protein 
fraction by breaking their interactions with the polar head groups of the membranes or 
with the IMPs using high pH or high-ionic-strength washes. The most widely used high 
pH buffers are sodium carbonate and sodium hydroxide, see e.g.53. For ionic 
dissociation, typical salts include sodium chloride, potassium chloride, sodium 
bromide, and potassium bromide. Lipids can interfere with downstream analyses (e.g. 
enzymatic digestion and liquid chromatography) and the most widely used method for 
removal involves protein precipitation by adding methanol/chloroform54. Lipids 
partition into the chloroform layer and proteins precipitate at the chloroform/aqueous 
methanol interface. Other methods include cold acetone55 (alone or in combination with 
other organic solvents) precipitation, TCA56 (trichloroacetic acid) precipitation 
followed by acetone wash or ethanol treatment57. 
1.2.2 Prediction of transmembrane domains (TMDs) 
The properties of the lipid bilayer limit the number of possible conformations of a 
membrane protein. Hence, there are large similarities between membrane proteins of 
different function and size, even if they originate from different types of membranes or 
different organisms. Using these similarities, important structural features can be 
predicted from the amino acid sequence alone. The most obvious feature that can be 
predicted is the number of transmembrane domains (TMDs) and where in the protein 
they are located. Several algorithms for prediction of TMDs have been developed; in 
this thesis the TMHMM58-59 algorithm was used. This is a method based on a Hidden 
Markov Model. Briefly, it consists of modeling different regions of a membrane protein 
by choosing possible states and picking the most likely topology by comparison with 
experimentally derived models. Other prediction algorithms include TopPred60, 
MEMSAT61, PHDhtm62, and HMMTOP63. 
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1.3 PROTEOMICS OF MEMBRANE PROTEINS 
Proteomics of integral membrane proteins has over the years proven to be challenging. 
The first paper dealing with a proteomic analysis of membrane proteins came as early 
as 197664. However, it was a two-dimensional gel electrophoresis experiment and at 
that time there were no methods to couple gel electrophoresis with identification of the 
proteins. Improved analysis was claimed by changing the experimental conditions and 
by that showing more protein spots. Hence, there was no way to know if the proteins 
detected were in fact membrane proteins or not. 
Membrane proteins are difficult to study mainly due to two reasons; their general low-
abundance and their hydrophobicity, which resists interaction with aqueous buffers. 
Major challenges in any proteomic experiment are i) the sample complexity and ii) the 
dynamic range problem, i.e. the wide concentration range of proteins within a sample 
from e.g. a cell in face of the limited dynamic range of the mass spectrometer. In the 
light of these facts, there is no surprise that membrane proteins are under-represented in 
proteomic investigations. 
1.3.1 Gel-based methods 
Conventional 2-DE is less suited for membrane proteins, since they are often basic 
proteins (high pI) at which 2D gels have reduced resolving power. Also, at their pI, 
most proteins are less soluble and membrane proteins tend to precipitate. However, a 
few gel-based methods suitable for hydrophobic proteins have been developed, 
including 16-benzyldimethyl-n-hexadecylammonium chloride (BAC)/SDS-PAGE65-66, 
blue native (BN)-PAGE67 and doubled SDS-PAGE68. 
In a 16-BAC/SDS-PAGE analysis, the proteins are separated according to molecular 
mass in a discontinuous acidic gradient (pH 4.0-1.5) using the cationic detergent 16-
BAC in the first dimension and standard SDS-PAGE in the second dimension. 
Although the proteins are separated my mass in both dimensions, the two detergents 
(16-BAC and SDS) have different binding properties, which allows for separation of 
proteins of similar molecular weight. The method has been used to identify 
mitochondrial proteins, human platelet membrane proteins and synaptic vesicle 
proteins. 16-BAC seems to be more efficient than conventional 2-DE at transfer into 
the second dimension69, but still remains the problem of inefficient in-gel digestion 
and/or extraction, which hinder protein identification44. 
BN-PAGE was developed for determination of the mass and oligomeric state of 
mitochondrial membrane protein complexes67,70. The method maintains enzyme 
activity and native protein-protein interactions due to use of mild detergents and a 
running pH of 7.5. The proteins are first solubilized in a mild, nonionic detergent (e.g. 
digitonin or Triton X-100) after which the anionic dye Coomassie brilliant blue G-250 
is added. The Coomassie dye has a relatively poor solubility in water and therefore 
binds to the hydrophobic surfaces of the proteins. The net negative charge of the 
protein-dye complexes confers electrophoretic mobility, aqueous solubility and reduced 
aggregation. To further resolve the individual components of the protein complexes, a 
second dimension SDS-PAGE is added. BN-PAGE has been quite successful in the 
identification of integral membrane proteins from E. coli71 and rat mitochondria72.  
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In a doubled SDS-PAGE analysis, a low percentage (10 %) acrylamide gel is used for 
the first dimension and a high percentage one (16 %) is used for the second dimension. 
Hydrophobic proteins tend to migrate faster in the first dimension due to the binding of 
more SDS but approach normal migration rates in the higher concentration of the 
second dimension, resulting in a different migration pattern than hydrophilic proteins68. 
This facilitates spot picking for subsequent identification analysis. The method has 
been used to identify proteins from synaptic vesicles73 and mitochondria42.  
Even though improvements have been made in the field of gel-based methods for 
detection of membrane proteins, problems still reside concerning labor-intensive and 
tedious workflow, limited number of proteins resolved (usually in the range of 100s) 
and inefficient protein identification. 
1.3.2 Shotgun methods 
It has become increasingly popular to use shotgun approaches where the proteins are 
digested into peptides followed by mass spectrometry based identification and 
quantification12,74 (figure 3).  
 
 
 
 
One of the advantages of using the shotgun approach is that peptides are generally more 
soluble than proteins in aqueous environments. This is especially an advantage when 
analyzing membrane proteins. However, sample complexity becomes an even greater 
issue, when thousands of digested proteins yield several hundreds of thousands of 
peptides. In 2-DE, validation of protein identifications can be carried out by using pI 
and molecular weight, and this parameter is lost in shotgun experiments. However, 
methods exist to estimate the false discovery rates of the database searches75.   
Shotgun proteomics methods have successfully been used for the study of membrane 
proteins43,76-77.  
1.3.2.1 Membrane protein solubilization 
The main issue concerning membrane proteins in shotgun approaches is protein 
solubilization. Keeping the proteins in solution without aggregation is essential for 
efficient enzymatic cleavage. The hydrophobic domains of membrane proteins resist 
exposure to aqueous solvents, causing aggregation, adsorption and precipitation which 
could lead to sample loss and incomplete digestion. Thus, one must choose reagents 
that maintain membrane protein solubility, without interfering with downstream 
analysis.  
Figure 3. Shotgun proteomic workflow. 
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Solubilizing agents can be divided into chaotropes, detergents, organic solvents and 
organic acids. Chaotropes are strong denaturing agents that stabilize unfolded proteins 
via hydrogen bonds and electrostatic interactions78-79. The most common ones are urea, 
thiourea and guanidium chloride. Thiourea is better than urea at breaking hydrophobic 
interactions why it is preferred for membrane protein solubilization, however it can 
inhibit proteases80. Chaotropes do not interfere with standard LC-MS/MS analyses. 
Detergents are a class of amphipathic molecules containing both hydrophilic and 
hydrophobic domains. They can self-associate into micelles and bind to hydrophobic 
surfaces such as the TMDs of membrane proteins. Detergents are classified into four 
groups; linear-chain ionic, nonionic, bile acid and zwitterionic. Ionic detergents have a 
cationic or anionic head group attached to a hydrocarbon chain. The classic example of 
an anionic detergent is SDS, which is extremely efficient at solubilizing and denaturing 
proteins81. However, SDS can interfere with enzymatic digestion (by steric hindrance) 
and can be difficult to remove82. SDS may also interfere with LC analyses and suppress 
ionization by MALDI and ESI. Nonionic detergents have a polar head group and a 
hydrophobic tail. They disrupt lipid-lipid interactions and lipid-protein interactions, but 
are generally less efficient at disrupting protein-protein interactions, and because of this 
nonionic detergents are considered relatively mild detergents. Examples are Triton X-
100, NP-40 and n-octyl glucoside (OG). In general, nonionic detergents at low 
concentrations are compatible with downstream analyses; however Triton X-100 tends 
to be problematic for MALDI and ESI. Bile acid salts are ionic detergents, but their 
conformation differs from the linear-chain ionic detergents. They are instead steroidal 
compounds, with a polar and apolar face, and they have less solubilizing capacities. 
However, an advantage of bile acids is that they precipitate at low pH and thus can be 
readily removed from solution prior to downstream analyses. Examples are sodium 
deoxycholate (SDC) and sodium cholate. Zwitterionic (both positively and negatively 
charged) detergents have intermediate properties with better solubilizing capacities than 
bile acids/nonionic detergents but not as good as the linear-chain ionic detergents. They 
do not interfere with trypsin digestion or ESI, but can suppress ionization by MALDI.     
As already mentioned, many of the most powerful solubilizing agents are not 
compatible with downstream analyses83. To circumvent this problem, MS-compatible 
detergents have been introduced. These include RapiGest (Waters)84, PPS (Protein 
Discovery)85 and Invitrosol (Invitrogen). RapiGest and PPS are acid-labile reagents 
which break down into non-interfering byproducts upon hydrolysis. Invitrosol exist in 
two variants, one MALDI-compatible and one LC/MS-compatible, where the first one 
do not interfere with peptide/protein analysis and the second one have orthogonal LC 
elution to most peptides. The MS-compatible detergents seem to perform relatively 
well at solubilizing membrane proteins in comparison with standard detergents.  
Organic solvents are an alternative to detergents to facilitate enzymatic digestion. Due 
to their increased hydrophobicity relative water, they have stabilizing effects on 
nonpolar proteins that are unfolded. Organic solvents also have disruptive effects on the 
membrane and especially methanol has been proven to be efficient in aiding tryptic 
digestion of membrane proteins86-88. Organic solvents are directly compatible with 
downstream analyses and can be removed by evaporation, reducing potential sample 
loss. 
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Organic acids, e.g. formic acid (FA) or trifluoroacetic acid (TFA) can also disrupt 
membranes and solubilize membrane proteins. Usually, the membrane fraction is 
solubilized in 80-90 % organic acid and before digestion the sample is diluted to a more 
appropriate concentration for trypsin89. Alternatively, other proteases are used for 
cleavage, e.g. cyanogen bromide (CNBr)12-13.  
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1.4 QUANTIFICATION AND DATA ANALYSIS 
Different methods have been developed to obtain the abundances of the proteins that 
have been identified in a proteomic experiment. In a 2-DE experiment, the staining 
intensities of the gel spots are used for a relative comparison. In shotgun experiments, 
the methods for quantification are usually relative, meaning a comparison of peptides 
or proteins between experiments. Absolute measurement of protein concentrations by 
mass spectrometry is also possible by e.g. SRM (selected reaction monitoring).    
Proteomic experiments often generate long lists of identified proteins and it can be very 
time-consuming to analyze the data. Therefore, programs and tools have been 
developed that enable visualization of the data in order to identify general trends and 
patterns. This kind of research is performed within the bioinformatic field. 
Bioinformatics is becoming increasingly important in aiding the proteomic 
investigators to extract the biological meanings of the experiments. 
1.4.1 Quantification 
In top-down proteomics, using e.g. MALDI-TOF MS, the quantification is based on the 
intensity of the peaks representing the proteins. The higher intensity, the more of the 
protein is expressed in that particular sample.  
In bottom-up proteomic experiments, where the proteins have been digested into 
peptides, quantification is instead performed on a peptide level. This can be done in a 
label-free manor or by using some kind of labeling of the peptides. Label-free 
quantification is performed by either measuring the intensities of the peptide peaks 
generated in the chromatography step or by spectral counting in the MS step (see 
e.g.90). Peptide labeling for quantification can be performed either in vivo by metabolic 
labeling during cell growth or in vitro after cell lysis. The in vitro labeling can be 
further divided into enzymatic or chemical modification labeling.  
The most common type of metabolic labeling is SILAC (stable isotope labeling by 
amino acids in cell culture)91. In brief, two populations of cell culture are grown 
separately, one with growth medium containing normal amino acids and the other with 
heavy isotope labeled amino acids. The medium can for example contain arginine 
labeled with 13C instead of normal 12C. This labeled arginine is subsequently 
incorporated into all the proteins in those cells. The cells are then combined and 
analyzed together and relative quantification is performed by comparing the intensity of 
labeled and non-labeled peptides in the MS spectrum. 
In enzymatic in vitro labeling, enzymes (Glu-C or trypsin) are used to incorporate 18O 
during protein digestion92-93. One drawback of this method is that not all peptides are 
labeled and hence the quantification becomes less reliable. 
The most common chemical modification labeling techniques are ICAT94 (isotope-
coded affinity tag) and iTRAQ95 (isobaric tags for relative and absolute quantification). 
In ICAT labeling, the cysteine residues are labeled with a mass tag containing either 
eight hydrogens (light reagent) or eight deuteriums (heavy reagent). After mixing and 
digestion, the cysteine-containing peptides are captured using avidin affinity 
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chromatography. Since not all peptides contain cysteines, this will also reduce the 
sample complexity. iTRAQ labeling targets primary amines in the peptides; hence all 
tryptic peptides will contain at least one iTRAQ label at the N-terminus. However, 
since trypsin cleaves after arginine and lysine, both having a primary amine, most 
peptides will have an additional label. The iTRAQ labels are isobaric, i.e. they have the 
same mass, and they also have the same chromatographic properties. As a result, 
peptides labeled with different tags will co-elute in the LC step as well as give rise to 
one single peak in the first MS part. What distinguish the individual tags are their 
fragmentation patterns in the MS/MS part, giving rise to reporter ions of different 
masses that subsequently can be quantified (figure 4). At present, up to eight samples 
can be labeled and quantified in parallel using iTRAQ labels.  
Figure 4. The iTRAQ isobaric tag consists of three groups; the peptide 
reactive group, the balance group and the reporter group. The reporter 
ions are used for quantification. 
 14 
 
1.4.2 Statistics and Biological interpretation 
The output from a proteomic experiment is not unusually a very long list of proteins 
with corresponding abundance data. To assist the data analysis, several statistical and 
bioinformatic tools are available.   
To get an overview of the data and identify trends, groups or outliers, an unsupervised 
principal component analysis (PCA)96 can be performed. In papers III and IV, this was 
done using Simca-P+ (Umetrics AB). In contrast, OPLS97 (orthogonal projections to 
latent structures) is a supervised prediction method suitable when the number of 
variables (proteins) greatly exceeds the number of observations (samples). OPLS 
maximizes the covariance and correlation between x and y data (e.g. x being the protein 
id and quantity and y the disease state) and removes structured noise in the x data that is 
orthogonal (unrelated) to the response, y. Using OPLS, prediction models can be 
created and proteins responsible for separating two groups can be identified.  
There are several software tools for functional analysis of proteomic data. Ingenuity 
pathway analysis (Ingenuity Systems), which was used in papers III and IV, can be 
used to organize proteins into networks and pathways. Other similar tools are 
DAVID98, PANTHER99, ProteinCenter (Proxeon) and FunCoup100, where proteins are 
organized into groups of molecular functions, protein families, biological processes and 
pathways.  
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1.5 VALIDATION 
In proteomic experiments, instrument time and sometimes reagents can be quite costly, 
why a limited number of samples can be included. This can be problematic from a 
statistical point of view and therefore validation of the findings is an important aspect. 
Usually a different technical platform is chosen and if possible more samples are 
included. Common techniques for validation are different immunoblotting methods, 
e.g. western blotting and immunohistochemistry (IHC). Western blotting is a well-
established technique where the samples are first separated in a normal SDS-PAGE 
system after which the proteins are transferred to a membrane (e.g. nitrocellulose). The 
protein of interest is then probed with a primary antibody, recognizing only that protein, 
after which a secondary antibody (linked to a reporter enzyme) towards the primary 
antibody is used to enhance and visualize the protein-antibody complex. Western 
blotting is regarded as a semi-quantitative method. IHC is another established 
immunoblotting method to determine protein expression in a tissue. Here, information 
on protein expression levels comes together with information about the localization of 
the protein in the cells; i.e. if it is expressed in the nucleus, the cytoplasm or the 
membrane, and in what type of cells. Briefly, tissue sections are prepared and incubated 
with a primary antibody directed against the protein of interest, and subsequently with a 
secondary antibody directed against the primary antibody. In analogy with western 
blotting, the secondary antibody is linked to a reporter enzyme, which enables 
visualization. ELISA (enzyme-linked immunosorbent assay) is another immunoblotting 
technique frequently used. 
Selected reaction monitoring (SRM) is a method for targeted quantitative analysis of 
peptides in cells or fluids101-103. Usually a triple quadrupole mass spectrometer is 
utilized. In peptide SRM selected peptides are fragmented and specific fragments are 
used for quantification. In addition to validating the identification, an absolute 
measurement of the protein can be obtained by the use of stable isotope standards. 
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1.6 LUNG CANCER 
Lung cancer is globally the most commonly diagnosed type of cancer and also the most 
common cause of cancer death104. There are two major types of lung cancer with 
distinct clinical characteristics and behavior, namely small cell lung cancer (SCLC) and 
non-small cell lung cancer (NSCLC). SCLC, which is the type studied in paper I, 
represents approximately 15 % of lung cancer cases and is strongly induced by 
smoking. It is very aggressive and it has often already begun to spread to form distant 
metastases at the time of diagnosis. SCLC is highly sensitive to chemotherapy and 
radiotherapy, but after an initial response, resistant clones start growing and the disease 
rapidly progresses105.   
 
1.6.1 Chemotherapy and drug resistance 
Cytotoxic drugs, or chemotherapy, usually targets DNA and are more or less unspecific 
in the sense that both cancer cells and normal cells are affected. It was the use of 
mustard gas and other chemical warfare agents during world wars I and II that initiated 
research on their possible therapeutic potentials. Soldiers exposed to these agents 
displayed decreased white blood cell counts and showed lymphotoxic symptoms106. 
Mustine, a mustard gas analogue, was subsequently used in treatment of leukemia, and 
it was suggested that its mechanism of action was due to alkylation. Since then several 
cytotoxic drugs have been developed targeting DNA or associated processes. Apart 
from alkylating agents, cytotoxic drugs include antimetabolites (interfere with 
nucleotide metabolism), topoisomerase inhibitors (interfere with DNA replication), 
antitumor antibiotics (inhibit replication and/or induce cleavage of DNA) and tubulin 
interacting agents (inhibit mitosis and induce apoptosis).  
Doxorubicin, an antitumor antibiotic, was originally isolated from bacteria, and it 
seems to have several cytotoxic effects. Through intercalation (fitting between base 
pairs in DNA) doxorubicin inhibits replication, but it has also been shown to act as a 
topoisomerase II inhibitor107.  
A major limitation in chemotherapy is that many tumors are resistant to specific 
cytotoxic drugs (primary resistance), or develop resistance during treatment (secondary 
resistance). Typical reasons for resistance are increased drug efflux, decreased drug 
uptake, increased drug metabolism, alteration of the drug target or resistance to 
apoptosis. Doxorubicin resistance in SCLC has been shown to be due to up-regulation 
of MRP1108 (multidrug resistance-associated protein 1), however resistance to 
anthracyclines (e.g. Doxorubicin) is generally considered multi-factorial109. 
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1.7 ADRENAL GLAND 
The adrenal glands are named for their location relative to the kidneys. The term 
adrenal comes from ad- (Latin, “near”) and renes (Latin, “kidney”). Sitting on top of 
the kidneys, they are endocrine glands mainly responsible for releasing hormones in 
conjunction with stress through the synthesis of corticosteroids such as cortisol and 
adrenaline. Adrenal glands affect kidney function through secretion of aldosterone, a 
hormone involved in blood pressure regulation. Each adrenal gland is separated into 
two structures, the cortex and the medulla, both of which produce hormones. The 
cortex mainly produces the steroid hormones cortisol, aldosterone and androgens, while 
the medulla produces adrenaline and noradrenaline. The cortex comprises three distinct 
regions; zona glomerulosa, zona fasciculata and zona reticularis. The first region 
produces aldosterone, while the second and the third regions produce cortisol. The cells 
that make up these three regions contain lipid droplets containing cholesterol, which 
can be converted into the steroid hormones. 
Aldosterone controls the salt content of the body and by that also the blood pressure. 
The amount of aldosterone produced is controlled, in part, by a protein from the kidney, 
renin. When the blood pressure falls, the amount of renin is increased. Renin converts 
angiotensinogen to angiotensin I, which in turn is converted to angiotensin II. This 
results in increased aldosterone production from the adrenal cortex, which acts on the 
kidneys to retain more salt. The salt is followed by water, which results in increased 
blood volume, hence the blood pressure increases. Cortisol acts on cells in different 
tissues in influencing general metabolism, blood pressure and appetite. The amount of 
cortisol is controlled by the hormone ACTH (adrenocorticotrophic hormone), which is 
secreted by the pituitary gland. This secretion is in turn controlled by other hormones 
from the hypothalamus. The major stimulus to this sequence of hormone secretions is 
stress, and cortisol is therefore a key component of the “fight or flight” reaction in a 
moment of crisis. 
The adrenal medulla is essentially a part of the sympathetic division of the autonomic 
nervous system. The main product of the cells in the medulla is adrenaline, which is 
involved in the “fight or flight” reaction alongside cortisol. More adrenaline is 
produced under stress, by sympathetic nerve stimulation. Noradrenaline is a 
neurotransmitter, and is also secreted by the medulla but in much smaller amounts.110     
1.7.1 Adrenocortical tumors 
Adrenocortical tumors, the focus of paper III, have a relatively high prevalence in the 
general population of up to 9 % in autopsy studies111. However, malignancies are rare, 
with a yearly incidence of 2 per million inhabitants, but they have a poor prognosis112.  
Recent advances in the bioimaging field together with the more frequent use of 
computed tomography (CT) and magnetic resonance imaging (MRI) have increased the 
number of detected adrenocortical tumors113. These accidentally discovered tumors are 
called adrenal incidentalomas and the majority of them are benign and non-functioning 
adenomas114. Distinguishing between adrenocortical carcinomas (ACCs) and 
adrenocortical adenomas (ACAs) can be difficult. In the clinical decision making, the 
tumor size and the CT Hounsfield measurements are the most important features in 
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determining if the tissue alteration is benign or malignant. Masses less than 3 cm in 
diameter are usually benign; by contrast, if the mass is larger than 6 cm the probability 
of malignancy increases 115. Masses measuring between 3 and 6 cm are uncertain and 
since early resection of ACCs is the best chance of survival, an accurate diagnosis of a 
small tumor is very important 115. All tumors with a diameter larger than 4 cm are 
recommended to be resected 116. There is a need for more sufficient diagnostic tools, 
both from a diagnostic point of view but also to avoid unnecessary abdominal surgery. 
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1.8 SARCOIDOSIS 
Sarcoidosis, the disease studied in paper IV, commonly affects young and middle-aged 
adults and frequently presents with bilateral hilar lymphadenopathy, pulmonary 
infiltration, ocular and skin lesions. The liver, spleen, lymph nodes, salivary glands, 
heart, nervous system, muscles, bones and other organs may also be involved117.  
Sarcoidosis is a systemic granulomatous inflammatory disease where the lungs are 
involved in 90% of the patients118. It is a multi-factorial disease where genetic as well 
as environmental factors are relevant119-120. The clinical manifestations are 
heterogeneous and can be divided into two main groups. Patients with Löfgren’s 
syndrome have an acute onset with erythema nodosum and/or ankle arthritis, fever and 
bilateral hilar lymphadenopathy, are often HLA-DRB1-03pos, and usually resolve 
spontaneously121. On the other hand, non-Löfgren’s patients, accounting for 65 % in 
Scandinavia, usually have an insidious onset of the disease with a prolonged disease 
course, especially when they are HLA-DRB1-14/15pos 122.  
Alveolar macrophages (AMs) are implicated in the pathogenesis of sarcoidosis through 
multiple functions. They act as antigen-presenting cells (APCs) and express co-
stimulatory molecules such as CD40, CD80 and CD86 and interact with CD4 positive 
T-cells, stimulating adaptive responses (Th1)123. IFN-γ and TNF-α produced by 
activated T-cells are essential for the formation of non-caseating granulomas, which is 
the hallmark of sarcoidosis124.  
The etiology of sarcoidosis is unknown, however some antigen candidates have been 
proposed as the cause of the disease, such as Mycobacterium tuberculosis antigen 
mKatG125 and Propionibacterium acne126-127. Also autoimmunity responses to vimentin 
has been observed in sarcoidosis patients128. 
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2 THE PRESENT STUDY 
 
2.1 AIMS 
The overall aim of this thesis was to develop a high throughput and reproducible 
method for proteomics on membrane proteins. The method had to be applicable to 
different materials since a downstream aim was to use the method to analyze clinical 
tissue in order to identify potential biomarkers or new therapeutic targets. 
 
The specific aims were the following: 
 
Paper I: To develop a membrane proteomics method, using cell line material. 
 
Paper II: Explore the possibilities of using peptide pI and retention time data to 
increase the information content of proteomic investigations. 
 
Paper III: Use the method developed in paper I on adrenocortical tumor tissue in 
order to shed light on the biology behind malignancy and to find markers that 
differentiate benign tumor from malignant. 
 
Paper IV: Characterize and describe altered pathways in alveolar macrophages from 
Sarcoidosis patients, by looking at the membrane-associated protein population. 
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2.2 MATERIALS AND METHODS 
A detailed description of the methods used can be found in each paper (I-IV). A brief 
description and comments are presented below.  
2.2.1 Cell and tissue samples 
In papers I-II two human cell lines were used; the SCLC cell lines H69 and H69AR. 
H69AR cells were incubated with 0.8 μM Doxorubicin twice monthly in order to 
maintain the resistant phenotype. The cells were cultured in humidified air in 
incubators under controlled conditions with a temperature of 37°C and at 5 % CO2. In 
paper II, two different samples were used for the investigations of retention time 
effects. One was a dog plasma sample consisting of the supernatant from acetonitrile 
precipitated plasma and the second sample was a commercial human liver microsome 
preparation. In paper III, adrenocortical tumor tissue samples were used. The tumor 
tissue analyzed contained more than 70% tumor cells. Diagnostic criteria for 
malignancy were vascular invasion, invasion of surrounding organs and/or presence of 
distant metastasis. In cases where these criteria were not fulfilled the histopathological 
criteria proposed by Weiss was used129. Cases with high nuclear grade, increased 
mitotic figures and tumor necrosis were suspected to be malignant. In paper IV, 
bronchoscopy was performed on eight sarcoidosis patients within three months after 
onset of symptoms, as part of the initial diagnostic routine investigation, and on six 
healthy controls, as previously described130. The diagnostic criteria for sarcoidosis 
patients were in accordance with the WASOG criteria118: in line with sarcoidosis were 
symptoms, chest radiographic changes and pulmonary function tests, as well as the 
presence of granulomas in lung biopsies, and an increased CD4/CD8 ratio ≥ 3.5 on 
BAL T-cells. Alveolar macrophages were isolated from BAL cells by PercollTM two 
phase density gradient ρ1= 1.062 g/ml and ρ2= 1.08 g/ml. 
2.2.2 Microsomal preparation 
Microsomes were prepared from both cells (papers I, II, IV) and tissue (paper III). 
Briefly, cell- or tissue homogenates were sonicated to break the cells and after a low-
speed centrifugation they were subjected to ultracentrifugation at 100 000 x g for 1 h at 
4°C to pellet the microsomes. Membrane-associated proteins were separated from 
integral membrane proteins by a high salt wash (2.5 M NaBr). The microsomal 
fractions were precipitated according to the method described by Wessel and Flügge54. 
Proteins were then solubilized in a buffer containing SDS.  
2.2.3 Digestion and iTRAQ labeling 
Proteins were digested by trypsin after dilution of the SDS concentration. Peptides were 
then labeled with iTRAQ; in papers I-II a 4-plex kit was used and in papers III-IV an 
8-plex kit was used. This means that either four or eight samples can be labeled and 
pooled into one sample. In papers III-IV, an internal standard was included to be able 
to compare samples across experiments. This was done by pooling aliquots from the 
individual samples to one pooled standard, which was iTRAQ labeled and included in 
each iTRAQ experiment.  
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2.2.4 Isoelectric focusing 
In all papers (I-IV), the peptides were separated by narrow range isoelectric focusing 
(IEF). Tryptic peptide samples were dissolved in 8 M urea. Narrow range IPG-strips for 
peptide focusing (pH 3.4 - 4.8 or 3.7 - 4.9, 24 cm long) together with dry sample 
application gels were kindly supplied by GE Healthcare Bio-Sciences AB, Uppsala, 
Sweden. The application gels were rehydrated in sample over night while the strips 
were rehydrated over night in 8 M urea and 1 % Pharmalyte™ 2.5-5. The IPG strips 
were put in the focusing tray and the application gels containing the samples were 
placed on the anodic end of the IPG strips with filter paper between the application gels 
and the electrodes. The strips were covered with mineral oil and the focusing was 
performed until 100 kVh had been reached. After focusing, peptides were extracted 
from the strips by a prototype liquid handling robot, kindly supplied by GE Healthcare 
Bio-Sciences AB. A plastic device with 72 wells was put onto each strip and MQ water 
was added to each well. After 30 minutes incubation, the liquid was transferred to a 96 
well plate and the extraction was repeated 2 more times. Samples were then freeze 
dried and kept at -20 ºC.  Prior to analysis, each fraction was re-suspended in 8 μl 3% 
acetonitrile and 0.1% formic acid. 
2.2.5 LC-MS/MS analyses 
2.2.5.1 LC-MALDI-TOF/TOF 
In papers I-II, the LC-MS/MS set-up was an off-line LC system coupled to a MALDI 
spotter. The samples were subsequently analyzed using an ABI 4800 MALDI-
TOF/TOF. Briefly, fractions from the IEF analysis were further fractionated by nanoLC 
chromatography, using a monolithic column. Monolithic columns have lower back 
pressure than traditional C18 columns, hence higher flow-rates and shorter gradient 
times can be used. The LC system was coupled to a MALDI spotter onto which 
fractions were automatically spotted together with matrix solution (CHCA). The 
MALDI-TOF/TOF mass spectrometer was set to perform data acquisition in the mass 
range of 700-4000 m/z. In each MS spectrum, maximum 10-15 peptides were chosen 
(only peptides above a set S/N threshold, usually 80-100) for fragmentation, starting 
with the strongest peptide. 
2.2.5.2 LC-Q-TOF MS 
In paper II, retention time analyses were performed on a UPLC-QTOF Ultima Global 
instrument combination. UPLC (ultra performance LC) enables faster separations with 
maintained separation and resolution capabilities due to small particle size in the 
columns (<2 µm).   
2.2.5.3 LC-Orbitrap MS 
In papers III-IV, the set-up was a nanoLC-Orbitrap MS system. Fractions from the 
IEF separation was loaded onto an Agilent HPLC 1200 system for online reversed-
phase nano-LC using a C18 column. Acquisition in the MS system proceeded in ~3.5 s 
scan cycles. The top 5 ions from the full scan MS were selected firstly for collision 
induced dissociation (CID) with MS/MS detection in the ion trap, and finally for high 
energy collision dissociation (HCD) with MS/MS detection in the Orbitrap.  
   23 
 
2.2.6 Data analysis and statistics 
In papers I-II, peptide identification was carried out using the Paragon algorithm 131 in 
the ProteinPilot 2.0 software package. The searches were performed against the IPI 
database or NCBI non-redundant, limited to human sequences. In papers III-IV, the 
MS/MS spectra were searched by Mascot 2.2 using Proteome Discoverer 1.1 against 
the IPI human target decoy protein sequence database. 
2.2.6.1 Membrane protein database 
To evaluate membrane protein content, an in-house database was built and searched 
against. This database was constructed by first extracting all translated human 
sequences from ENSEMBL and then tagging them according to number of 
transmembrane segments predicted using the TMHMM algorithm58. The sequences 
were tagged with 0 tms, 1 tms or 2+ tms. 
2.2.6.2 pI predictions 
In papers I-II, the peptide pI values were predicted using an algorithm kindly provided 
by Stephenson et al17. It was previously observed that deamidation of Asn and Gln (i.e. 
conversion to Asp and Glu, respectively) renders peptides significantly more acidic and 
they thus show up as outliers in pI-plots132.  Before calculating the theoretical pI values, 
an in-house script was used to convert the Asn → Asp and Gln → Glu, where 
appropriate.  
2.2.6.3 Retention time predictions 
In paper II, retention time predictions were performed using SSRCalc (available at 
http://hs2.proteome.ca/SSRCalc/SSRCalc33B.html). In order to use SSRCalc online, 
one has to trim the equation according to the LC-system and gradient used. This can be 
done in different ways, where one is to use a digest of a known protein (e.g. BSA), 
extract the experimental retention times of identified peptides and plot these against the 
hydrophobicities of the peptides (calculated in the SSRCalc). From this dependence, 
RT=A+B*(HP), the A and B parameters are determined where A is the gradient delay 
time and B is a value related to the slope of the acetonitrile gradient. The A and B 
parameters are then used in the SSRCalc program, together with information about 
column properties, to predict retention times of other identified peptides in any runs 
under the same conditions. Using 31 identified BSA peptides (Mascot scores above 30) 
we determined the A and B parameters for our system. Plotting observed retention 
times against predicted, we could see a linear correlation with a R2 value of 0.93, 
indicating adequate predicting of the SSRCalc algorithm. 
2.2.6.4 Statistics 
Univariate data analysis (papers III-IV) was carried out using Significance Analysis of 
Microarrays (SAM) 133, version 3.09, as an Excel add-in. SAM uses permutations of 
the repeated measurements to estimate the percentage of genes/proteins identified by 
chance, the false discovery rate (FDR). Multivariate data analysis was carried out 
using Simca-P+ (see section 1.4.2).  
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2.2.7 Western blot and immunohistochemistry 
For validation of identified deregulated proteins (papers I, III), western blot and 
immunohistochemical (IHC) analyses were performed. For western blot, proteins were 
first separated on a SDS-PAGE, transferred to a nitrocellulose membrane after which 
the protein(s) of interest were probed with antibodies. IHC analyses in paper III were 
performed on tissue that was fixed routinely in 4% formaldehyde buffered solution and 
paraffin embedded. All adrenal tumors were studied by routine histochemical staining 
i.e. haematoxylin and eosin staining. To perform immunohistochemical analysis tissue 
sections were cut at 4 µm, deparaffinized and rehydrated. Antigen retrieval by heating 
in citrate buffer was performed to obtain a distinct signal without interfering 
background. All antibodies were tested at different dilution with and without antigen 
retrieval technique. As positive controls, tissue samples from pancreatic gland 
(NDUFA13/GRIM-19) and normal adrenal gland (STAT-3) were used. Negative 
controls were performed by replacing the primary antibody with phosphate buffer. 
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2.3 RESULTS AND DISCUSSION 
 
2.3.1 Microsomal preparation 
To develop a reproducible high-throughput method for maximal coverage of the 
membrane proteome, we aimed to keep the number of sample preparation steps to a 
minimum. Therefore, we used a microsomal fractionation technique that should also be 
applicable to different samples, e.g. cells and tissues. The experimental workflow is 
outlined in figure 5. In short, the sample at hand was first homogenized with 
appropriate method after which it was sonicated to break up the cells and the 
membranes. The membranes will then form vesicles, i.e. microsomes. The homogenate 
was first centrifuged at low speed to remove cell debris, after which an 
ultracentrifugation at 100 000 x g was performed to pellet the microsomes. The 
supernatant now contained soluble proteins (SP). The pelleted microsomes were then 
washed with high salt buffer (2.5 M NaBr) to remove loosely attached proteins 
(membrane-associated proteins, MAP). A second ultracentrifugation was performed to 
pellet the membrane (microsomal) proteins (MP). The microsomal fraction 
predominately contained ER membranes, and to some extent membranes from Golgi, 
mitochondria and plasma membrane.  
2.3.2 Delipidation, solubilization and digestion 
The next step in the preparation was to remove lipids, which can interfere with the 
enzymatic digestion. This was done by using chloroform/methanol precipitation54, one 
of the most widely used methods, whereby lipids will partition into the chloroform 
layer and proteins will precipitate at the chloroform/methanol interface.  
Before digestion, the microsomal proteins are solubilized in a buffer containing 
detergent. Sodium dodecyl sulfate (SDS), the detergent of our choice, is the classic 
example of a detergent. It is an anionic detergent, meaning it has an anionic head group 
attached to a hydrocarbon chain. SDS is extremely efficient at solubilizing proteins but 
it has drawbacks concerning downstream applications. It is not compatible with liquid 
chromatography (LC) analyses and it can suppress ionization by MALDI and ESI. In 
our case, however, this was not a problem since we digest and clean the sample before 
these analyses. The microsomal proteins were digested using trypsin. The SDS 
concentration was first reduced to 0.1 %, to keep trypsin in an active form. 
2.3.3 iTRAQ labeling 
The digested samples were labeled with iTRAQ. In paper I, the 4-plex kit was used; 
two samples from the sensitive cell line and two samples from the resistant cell line. In 
papers III and IV, the 8-plex kit was instead used. Since we had 14 samples in each of 
these studies, two iTRAQ labeling sets were used per study and in each one we 
included an internal standard. The internal standard samples were created by pooling 
equal amounts from each individual sample, and the iTRAQ reporter intensities were 
normalized using the intensity of the internal standard. This way it was possible to 
compare samples even if they were run in different iTRAQ labeled pools. The samples 
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were cleaned by SCX after labeling to remove iTRAQ reagents and this step also 
removed most of the SDS.   
 
 
Figure 5. Experimental workflow. 
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2.3.4 Reproducibility of the microsomal preparation 
To evaluate the technical reproducibility of the microsomal preparation, protein 
concentration in the resulting fractions was measured. This showed high reproducibility 
with low coefficients of variance (CVs); 5 % for the total protein fraction, 3 % for the 
soluble protein fraction, 13 % for the MAP fraction and 6 % for the microsomal protein 
fraction, see Fig 2 in paper I. The reproducibility concerning protein composition was 
also investigated. The majority of the CVs were below 30 % and CVs above 30 % 
predominantly came from ions of low intensity which may explain the larger variation. 
The reported variation originates from technical and experimental variation, including 
differences in iTRAQ-labeling efficiencies, previously reported to be approximately 12 
% 134. 
 
2.3.5 Membrane protein content 
In paper I and paper III, the microsomal protein (MP) fractions were analyzed. In 
paper IV, we instead analyzed the membrane-associated protein (MAP) fraction. The 
proportion of predicted integral membrane proteins ranged from 15 % (paper I) to ~22 
% (paper III). The predictions were based on searches against an in-house database 
which was constructed by first extracting all translated human sequences from 
ENSEMBL and then tagging them according to number of transmembrane segments 
predicted using the TMHMM algorithm58. The sequences were tagged with 0 tms 
(transmembrane segments), 1 tms or 2+ tms. The tags were divided into 1 and 2+ (two 
or more segments) to avoid assigning signal peptides as transmembrane segments. 
Proteins have a signal peptide in the beginning of their sequences directing them to the 
correct localization in the cell and this signal peptide is often of hydrophobic character. 
The proteins tagged with 1 tms were consequently considered as more uncertain 
membrane proteins. In paper I we also used ProteinCenter to analyze the data and then 
the reported proportion of membrane proteins were 48 %. ProteinCenter uses TMAP135 
in single sequence mode for prediction of membrane proteins. The original TMAP 
algorithm utilizes multiply aligned sequences for the predictions and when using 
TMAP on only a single sequence, the accuracy decreases, and it is therefore likely that 
the 48 % found is falsely too high. The total numbers of identified membrane proteins 
were 527 and 743 in paper I and paper III, respectively. Approximately 50 % of them 
contained more than two transmembrane segments. The proportion membrane proteins 
(~15-20 %) might seem low but one has to remember that these proteins are difficult to 
study for reasons discussed in the Background section. The preparation technique used 
here (microsomal enrichment) yields vesicles formed from all types of membranes in 
the cell (predominately ER membrane). These vesicles most probably contain trapped 
soluble proteins and since these are already in solution, they are easier to process. The 
membrane proteins need first to be solubilized for trypsin to get access for cleavage. By 
comparison, the predicted membrane protein content of an unfractionated sample was 
estimated to be 10 %; only ~3 % was predicted to contain more than 2 tms (data not 
shown), which means that by enrichment with our developed method, an increase of 
integral membrane proteins by ~300 % is reached.  
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The number of identified membrane proteins in papers I and III is comparable to 
other studies where similar approaches have been used. Scherl et al had, when using a 
similar membrane preparation technique on cultures of Staphyococcus aureus, a 
membrane protein content of 20 % 136. Another study on vascular endothelial cells 
identified 43 % membrane-associated proteins 137. This estimate was based on GO 
annotations, however it is difficult to decipher which GO terms have been used. 
Further, the term membrane-associated indicates that maybe not all proteins contained 
transmembrane segments per se, but can include peripheral membrane proteins as well. 
A characterization of the rat liver membrane proteome identified ~40 % predicted 
membrane proteins; approximately 50 % of these were predicted to contain more than 
two TMD’s88. However, since there were fewer proteins identified (~1600), the number 
of membrane proteins was lower. Also, methanol-assisted digestion was employed, 
which hinders direct comparison of the methods.  
2.3.6 Peptide fractionation 
We employed narrow range (pH ~3.5 – ~4.9) peptide isoelectric focusing (IEF) as the 
first dimension separation step before a standard liquid chromatography (LC) 
separation step. We showed that by doing this, the sample complexity was reduced 
since only about a third of all theoretical tryptic peptides focus in this pH range (figure 
5A). However, approximately 96 % of all human proteins were represented by at least 
one peptide. This reduction in complexity is a great advantage when working with low-
abundant proteins like membrane proteins. Recently, Chick et al performed a study on 
membrane protein enriched samples from rat liver using a similar approach with 
isoelectric focusing as a first separation step88. They identified 626 proteins containing 
at least one transmembrane segment by using a pH 3 - 10 focusing strip sectioned into 
24 fractions which were all analyzed by nano LC-MS/MS. The fact that approximately 
the same number of membrane proteins was identified by our approach (~500 in paper 
I and ~700 in paper III) using a much smaller pH interval (4.0 - 4.5) compared to their 
broad pH range supports the idea to use narrow pH range in the focusing step. Further, 
this raises the question if an even narrower pH range would enable a deeper analysis 
into the (membrane) proteome. For the human proteome, even a pH-range as small as 
0.1 pH-units hold a considerable number of tryptic peptides (figure 5C). It must be 
stressed that plotted in figure 4 is a minimalistic estimation as the pI prediction was 
done using only fully tryptic, non-modified peptides. As recently shown, the 
complexity of proteome-wide tryptic digests may be far higher than theoretical enzyme 
cleavage predictions estimates101,138. Based on these facts, and given the high resolution 
demonstrated in paper I, it is clear that the use of pH-gradients <1.0 - 1.5 pH-units 
presents an important area of future research. 
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Figure 6. A plot of the predicted pI distribution among human tryptic peptides (included are peptides of 
lengths 4–60 amino acid residues, allowing for no missed cleavages). Approximately one third of the 
peptides have pI values between 3.5 and 4.5. (A) shows the distribution over 7 pH units, (B) over 1.5 pH 
units, (C) over 0.4 pH units and (D) over 0.05 pH units. X-axis defines the pI and on the y-axis the 
peptide count. The bar below the x-axis indicates the range covered in each subsequent plot. 
 
2.3.6.1 Separation efficiency of IEF 
To evaluate the efficiency of the IEF separation, the extent of overlap between 
consecutive fractions was investigated. First, extracted ion chromatograms of three 
randomly chosen precursors from the MALDI-MS run of all 72 IEF were generated 
(Fig 6 in paper I). As can be seen, precursors were observed in two or maximum three 
neighboring fractions. To evaluate the separation efficiency further, all peptides in three 
consecutive fractions were compared and peptides occurring in more than one fraction 
were identified. 8 % was found in both two fractions and less than 1 % was found in all 
three fractions (data not shown). This indicates a highly efficient separation for a 
complex peptide sample. 
2.3.7 pI and retention time predictions 
The IEF separation technique provides information about the pI of the peptides and this 
can be used to validate the peptide sequences matched to MS/MS spectra. The 
theoretical pI values of the peptides assigned with a confidence score ≥90 % were 
calculated using an algorithm kindly provided by Stephenson et al17,139. Figure 5 in 
paper I shows the distribution of calculated pI values of the peptides identified in one 
fraction analyzed by LC-MS/MS. Given adequate focusing and a well-performing 
prediction algorithm, all peptides in the fraction should have similar pI values. Indeed, 
the bulk peptide population of a representative fraction showed a standard deviation of 
0.05 pI units. However, a few peptides showed deviating pI values. When examining 
these peptides in more detail, it was observed that most of them were modified. As the 
peptide pI calculation is done for non-modified sequences, peptides which have a 
shifted pI due to a post-translational modification will show up as outliers. 
 30 
The work from paper I encouraged us to further explore the properties of narrow range 
peptide isoelectric focusing (IEF) as a separation strategy. In paper II we wanted to 
explore the possibilities of using a combination of narrow range peptide IEF and 
reversed phase chromatography to increase the information content of a proteomic 
analysis. Using the data generated in paper I for the peptide pI analysis and data from 
dog plasma and in vitro human liver microsomes for retention time analysis, 
experimental and predicted values for peptide pI and retention time were compared and 
general trends of peptide pI shifts, as well as shifts in retention time, induced by 
common modifications were analyzed. We observed that deamidations of glutamine 
and asparagines shift peptide pI by approximately 1.5 pI units, making the peptides 
more acidic. Additionally, a novel pI shift (+~0.4 pI units) was found associated with 
dethiomethyl Met modifications. Further, oxidation of methionine shortened the 
retention time of the modified peptides with 0.7 – 3.0 min (15 peptides; mean value 1.3 
min), formylation at the N-terminus increased the retention time with 0.6 – 5.9 min (10 
peptide pairs; mean value 2.8 min) and conversion of glutamate to pyro-glutamate 
prolonged the retention time with 2.5 – 7.1 min (4 peptide pairs; mean value 3.9 min). 
2.3.7.1 Possible applications 
To be able to use the predicted pI and retention time values, one relies heavily on the 
prediction algorithms at hand. While the behavior of non-modified fully tryptic 
peptides can be predicted with high accuracy in terms of both pI 17-18 and retention time 
140-141, post-translationally modified peptides have been less explored. Recent work has 
been presented on extending the functionality of pI-prediction algorithms to include 
PTMs142. Future efforts to improve such algorithms and open modification search 
engines can only benefit from the degree of accuracy provided using narrow range IPG-
IEF. An attractive application could be to use mass - pI - retention time filtering as a 
strategy for database reduction prior to open modification searches that is independent 
of MS/MS data acquisition. In such a strategy, a candidate list of protein accessions 
would be obtained by calculating which candidate peptide sequences fit in the recorded 
and calculated mass, pI and retention time windows. Such an approach could also take 
into consideration the most common modifications and amino acid alterations (Table 1 
in paper II). 
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2.3.8 Lung cancer resistance mechanisms 
In paper I, a small cell lung cancer cell line resistant to the cytotoxic drug Doxorubicin 
(H69AR) was analyzed and compared with its sensitive parental cell line (H69). Drug 
resistance is often associated with up-regulation of membrane-associated drug efflux 
systems and resistance to Doxorubicin has been shown to in part be due to an up-
regulation of multidrug resistance-associated protein 1 (MRP1), which is one of the 
most important members of the ATP-binding cassette (ABC) protein family108. ABC 
transporters are transmembrane proteins that utilize the energy of adenosine 
triphosphate (ATP) hydrolysis to carry out certain biological processes including 
translocation of various substrates across membranes and non-transport-related 
processes such as translation of RNA and DNA repair143. 
In our study, 48 proteins were found to be more than a 2-fold differentially expressed 
between the two cell lines. One of them, Serca 2, was found to be down-regulated in 
the resistant cell line and this was validated by western blot analyses, fig 8 in paper I. 
Serca 2 is a Ca2+ pump with 10 transmembrane segments located in the ER membrane, 
responsible for pumping Ca2+ into the ER lumen. Sensitivity to apoptosis correlates 
with the total ER Ca2+ load and depends on the ability of cells to transfer Ca2+ from the 
ER to the mitochondria144. Ca2+ levels in the ER play an important role in the cell’s 
ability to undergo apoptosis and down-regulation of the enzyme responsible for the 
influx of Ca2+ into the ER may contribute to the resistance phenotype of H69AR cells. 
Several cytoskeletal proteins were found to be up-regulated in the resistant cell line. 
These include plectin, vimentin and moesin. This could suggest a more rigid structure 
of these cells, making them less sensitive to environmental stress. Desmoplakin was 
down-regulated in H69AR. This protein is a component of desmosomes, intercellular 
junctions that tightly link adjacent cells. When culturing the cells, the resistant cells 
were less prone to grow in aggregates than the sensitive cells and this could be due to 
the down-regulation of desmoplakin. 
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2.3.9 Adrenocortical tumors 
In paper III, the microsomal proteins of eight ACCs and six ACAs were analyzed. In 
an initial supervised prediction analysis, one of the ACCs clustered with the ACAs. 
Since this had been observed when performing microarray studies on the same 
material145, this sample was removed from the subsequent analyses. Pathway analysis 
revealed that many proteins belonging to complex I in the mitochondrial respiratory 
chain (MRC) were down-regulated in ACCs compared to ACAs. A t-test was 
performed to identify significantly deregulated proteins and 69 were found to be up- or 
down-regulated. Aldolase A was up-regulated in ACCs compared to ACAs. This is a 
glycolytic enzyme responsible for the cleavage of the six-carbon sugar fructose 1,6-
biphosphate into the two three-carbon fragments glyceraldehyde 3-phosphate (GAP) 
and dihydroxyacetone phosphate (DHAP). This, together with the down-regulation of 
complex I proteins, indicates a metabolic shift in the ACCs where the glycolysis rate is 
higher and the MRC activity lower. This is known as the Warburg effect and is readily 
used in the clinic with the application of the imaging technique positron-emission 
tomography (PET) using the glucose analogue tracer 18fluorodeoxyglucose (FdG). 
IGF2 was up-regulated in ACCs and this is in agreement with several other studies on 
adrenocortical tumors145-148. The IGF2 gene is imprinted and is only expressed from the 
paternal allele. In the same region as IGF2, there are two other imprinted genes, H19 
and p57Kip2 which are expressed only from the maternal allele. The reason for IGF2 
overexpression in ACCs is often that there is a loss of heterozygosity and/or loss of 
imprinting, i.e. the paternal allele is expressed in two copies or the imprinting of the 
maternal allele is lost. This means that not only is IGF2 expression increased but the 
expression of the two other genes, H19 and p57Kip2 is lost or reduced. Since H19 is 
thought to be a tumor suppressor gene and p57Kip2 acts as a suppressor of cell cycle 
progression, this will further drive the tumorigenesis 149-150. IGF2 has affinity for both 
receptors IGF1R and IGF2R151. Upon binding to IGF1R, the receptor tyrosine kinase 
activity is triggered, which leads to phosphorylation of itself and its major substrate, the 
insulin receptor substrate 1 (IRS-1). Phosphorylated IRS-1 can activate the 
Ras/Raf/MAPK and PI3-kinase/Akt pathways, and depending on the cell type, 
stimulate proliferation, differentiation, or both152. PI3-kinase activation can lead to anti-
apoptotic signals, and components of this pathway are frequently amplified or mutated 
in cancers 153. Elevated expression levels of IGF2 have been found in several cancer 
forms such as colorectal carcinoma 154.  
One of the complex I proteins that was identified as down-regulated in ACCs was 
NDUFA13, also named GRIM-19 (Gene associated with Retinoic- and Interferon-
induced Mortality-19). GRIM-19 is a mitochondrial protein involved in complex I 
assembly and activity and is required for electron transfer activity 155. It has been shown 
that GRIM-19 deficient mouse blastocysts had alterations in the mitochondrial 
structure, morphology and cellular distribution156. Dysfunctional mitochondria could 
lead to inability of the cells to undergo mitochondria-mediated apoptosis. In our mass 
spectrometry data we did not see a complete loss of GRIM-19 expression, but a 2-fold 
difference in expression when comparing ACAs and ACCs. The identification and 
quantification of GRIM-19 was based on 2 peptides, one at position 61-68 and the other 
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at position 70-81. Interestingly, western blot analyses could not detect any GRIM-19 at 
all in the malignant tissue (fig 6B in paper III). This could of course be due to 
sensitivity issues of the anti-GRIM-19 antibody or that the protein is completely lost 
but it could also suggest a defective protein, as suggested in157. He et al report of an 
alternatively spliced GRIM-19 in kidney cancer tissue, resulting in a longer transcript 
with a premature stop codon after exon 3. This could lead to a truncated protein. The 
antibody used in our study recognizes the full-length protein and the reason for the 
absent signal in the western blot analyses could be inability of the antibody to recognize 
any modified form of the protein.  
Four benign tissues and four malignant tissues were evaluated for GRIM-19 expression 
with immunohistochemical methods. In the benign samples the expression patterns 
were grain-like (figure 7A). On the contrary, in the malignant samples there was a more 
general cytoplasmic staining pattern (figure 7B). This suggests a mitochondrial 
localization in ACAs and that this localization may have been lost in the ACCs, either 
due to loss of the protein or loss of functional protein. To check a possible role of 
STAT3 regulation by GRIM-19, STAT3 was analyzed by immunohistochemistry in the 
same tissues (figures 7C-D). There were no obvious differences between the benign 
and malignant tissues concerning STAT3 expression levels, but an indication of 
stronger staining in nuclei was observed for the malignant tissue, suggesting STAT3 
relocalization (figure 7D). In some cells in the benign tissue, a grain-like expression 
pattern was observed; the same could not be seen in the malignant tissue (figure 7E). 
This could indicate a STAT3 mitochondrial localization in ACAs.  
There could be a link between elevated expression levels of IGF2 and aldolase A and 
decreased expression of/non-functional GRIM-19. Activation of growth factor 
receptors leads to PI3K activation, which via AKT leads to increased glucose uptake 
and flux through the early part of glycolysis158-159. Additionally, tyrosine kinases, a 
common feature of oncogenes, can inhibit the later part of glycolysis through regulation 
of the M2 isoform of pyruvate kinase160 and thereby intermediates of glycolysis can be 
used for amino acid and nucleotide synthesis. The reason for increased glycolysis in the 
ACCs examined in this study could be due to a combination of impaired mitochondrial 
function, due to down-regulation or loss of functional GRIM-19, and activation of 
growth factor receptors through IGF2 signaling.  
In summary, by analyzing the microsomal protein composition of ACAs and ACCs, we 
observe a reduced expression of GRIM-19 in ACCs. It is not clear at this point if it is a 
down-regulation per se or a loss of functional GRIM-19, however indications point 
towards a re-localization of the protein, from mitochondria to the cytoplasm, and this 
re-localization could be due to a modified form of the protein in ACCs. Studies are on-
going to confirm this hypothesis. Loss of functional or re-localized GRIM-19 could 
lead to dysfunctional mitochondria and STAT3 hyperactivation, which in turn could 
drive the tumorigenesis in ACCs. Further, we observe an increased glycolysis rate in 
ACCs, which also, in part, could be caused by dysfunctional mitochondria. However, 
the reason for the shift in metabolism is most probably multi-factorial, where e.g. 
hypoxia also could play a role. IGF2, identified as up-regulated in ACCs by us and 
others, may contribute to this metabolic shift, which increases proliferation of tumor 
cells. 
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Figure7. Immunohistochemical analyses with anti-GRIM-19 (panels A and B) and anti-STAT3 
(panels C-E). GRIM-19 staining in ACAs had a grain-like pattern, suggesting mitochondrial 
localization (panel A). In ACCs there was a more cytoplasmic staining (panel B). There was an 
indication of nuclear staining of STAT3 in ACCs (panel D), which was not observed in ACAs 
(panel C). Some cells in ACAs showed a grain-like staining pattern for STAT3 (panel E). 
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2.3.10 Sarcoidosis 
In paper IV, we enriched for membrane-associated proteins from alveolar 
macrophages from eight sarcoidosis patients and six healthy controls. Alveolar 
macrophages were isolated from bronchoalveolar lavage (BAL) cells. By applying a 
shotgun proteomics approach on the MAP fraction, we obtained the protein profile on 
lung macrophages and a total of 1650 proteins were identified and relative quantitation 
was obtained on 423 proteins by using iTRAQ labeling. A PCA plot showed group 
clustering for sarcoidosis and controls, figure 3 in paper IV. The two clusters among 
the sarcoidosis patients can be explained by their diagnosis; non-Löfgren or Löfgren 
disease. An orthogonal projections to latent structures (OPLS) analysis was performed 
with healthy versus diseased. Proteins that had a small influence were removed 
iteratively to create a new predictive model. Accordingly, we reduced the number of 
proteins from 423 to 13 in a model with a predictability value Q2 = 0.718 (Q2 > 0.45 cut 
off to be considered as a good model) and a p-value of 0.0009 (figure 7 and table 2 in 
paper IV). Three of the proteins are involved in endocytic transport; MP1 (mitogen-
activated protein kinase scaffold protein 1), C11orf59 and RAB7A. MP1 and C11orf59 
are part of a protein complex called the Ragulator complex. This complex is anchored 
to lipid rafts in late endosome membranes via C11orf59, recruits mTORC1 to 
lysosomal membranes in amino acid signalling and is also involved in MAPK 
signalling161. Additionally, RAB7A has a role in the maturation of phagosomes162. One 
of the proteins is involved in host-virus interactions. i.e. complement component 1 Q 
subcomponent-binding protein163. The rest of the proteins in the OPLS model are 
involved in DNA repair, alcohol metabolism, protein folding and ribosomal activity. 
 
Pathway analysis showed that energy-related (ATP synthesis), as well as phagocytosis 
pathways were altered. The oxidative phosphorylation pathway (p-value 1.02E-10) 
showed a down-regulation in sarcoidosis at the level of complex I, III, IV and partially 
V from the mitochondrial respiration system. The lungs are exposed to oxidants either 
endogenously, e.g. from the mitochondrial electron transport or during phagocytosis, or 
by exogenous pollutants. Reactive oxygen species (ROS) include a variety of radicals; 
e.g. superoxide anion (O2.-), hydroxyl radical (.OH) and hydrogen peroxide (H2O2). 
Redox imbalance, which can be caused by increased ROS formation, is associated with 
chronic inflammation in several lung disorders; COPD164, asthma 165, acute lung injury, 
lung fibrosis and cancer 166. High concentration of ROS can trigger tissue damage and 
changes in signal transduction. Studies have shown that imbalance in redox status leads 
to activation of NFκβ where ROS are directly implicated as second messengers by 
regulating ubiquitination and degradation of Ikβ 167. In addition, it has been reported 
that the high exposure to oxidants induce mitochondrial dysfunction in the lungs 168 by 
oxidative damaged macromolecules (oxidatively dysfunctional proteins) which leads to 
increased protein degradation and dysfunction in mitochondria.  
The pyruvate metabolism pathway (p-value 7.45E-09) was up-regulated in the 
sarcoidosis group. Pyruvate has been shown to be an endogenous anti-inflammatory 
molecule by protecting cells from ROS and suppressing both TNF-α secretion and NF-
κB expression 169. The up-regulation of pyruvate metabolism that we observe could be 
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an effect of mitochondrial dysfunction and ROS formation which leads to an up-
regulation of endogenous pyruvate in order to protect the cells. 
Additionally, in the results from the pathway analyses we could observe an up-
regulation in phagocytosis related pathways in sarcoidosis, e.g. the Fcγ receptor-
mediated phagocytosis in macrophages (p-value 1.47E-05) and the Clathrin-mediated 
endocytosis signaling (p-value 9.64E-09) (figure 7), both in Löfgren and non-Löfgren 
sarcoidosis patients. Macrophages have several phagocytotic mechanisms; for instance 
they can be initiated by the Fcγ receptor (FcγR) which was found up-regulated in 
sarcoidosis. The Fc region from IgG binds to FcR on AMs and initiates the 
phagocytosis. This mechanism mediates internalization of pathogens (bacteria, virus 
and parasites) into membrane-derived vacuoles and phagosome system which finally 
leads to degradation of pathogens and the presentation of specific antigens to memory 
T-cells in the lungs170. Activation of FcR by IgG opsonised particles induce 
phosphorylation of tyrosines in ITAM (immunoreceptor tyrosine-based activation 
motif) on the FcR which leads to recruitment of other proteins such as phosphatase Src 
and 5’PI downstream in signaling171. The FcR mediates signal transductions that 
regulate production of ROS, modulate actin cytoskeleton172, and membrane fusion173. 
In summary, we report down-regulation of pathways related to the mitochondrial 
respiration system, which could lead to an imbalance in the oxidative homeostasis, in 
turn triggering ROS formation in sarcoidosis patients. This down-regulation was true 
only for non-Löfgren patients and this could in part explain their unresolved 
inflammation and prolonged disease course. The up-regulation of pathways related to 
pyruvate metabolism may be due to the cells trying to protect themselves from the 
increased ROS formation. We also observed up-regulation in phagocytosis-related 
pathways in sarcoidosis, which could be pathogen-mediated mechanisms of the 
alveolar macrophages. 
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2.4 GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES 
The overall aim of this thesis was to develop a proteomic method suitable for studies of 
integral membrane proteins in clinical material. Membrane proteins are under-
represented in proteomic investigations due to their general low-abundance and 
hydrophobicity. They are an important class of proteins, involved in cell-cell 
interactions, signaling and transport. Two of the papers in this thesis are more 
methodological, while the last two have a more biological/clinical focus. The general 
conclusions are: 
 Membrane protein identification 
15-22 % of the identified proteins were predicted to be membrane proteins. A 
predominant part of the membrane proteins originated from intracellular 
organelles, e.g. ER and mitochondria. The microsomal preparation method was 
shown to be reproducible and applicable to clinical material. The number of 
identified membrane proteins lies in line with top notations published so far. 
However the proportion soluble proteins in the fraction could be decreased and 
warrants further method development. 
 Isoelectric focusing 
Narrow range IEF reduces the sample complexity by 2/3 while maintaining 
high proteome coverage; ~96 % of all human proteins are represented by at 
least one peptide in the pH range of 3.5 – 5.0. This increases the possibility of 
identifying low-abundant proteins, e.g. membrane proteins, and thereby 
enables to dig deeper into the proteome. The theoretical peptide pIs can also be 
used to validate the sequences and could lead to more proteins being identified. 
In paper II we explored the possibility of using the peptide pI together with 
retention time and mass as a filter for database reduction prior to open 
modification searches.   
 Adrenocortical tumors 
Comparing the membrane proteome of ACCs with ACAs indicated a shift in 
metabolism towards increased glycolysis in favor of normal respiration via the 
electron transport chain in ACCs. GRIM-19 was found to be down-regulated in 
ACCs. This is a mitochondrial membrane protein required for correct assembly 
of complex I in the electron transport chain. It has further been shown to be a 
negative regulator of STAT3. Our analysis indicated a loss of mitochondrial 
localization of GRIM-19 in ACCs. This could have implications for the 
tumorigenesis of the ACCs, together with other factors such as elevated IGF2 
levels. 
 Sarcoidosis 
The membrane-associated protein population of alveolar macrophages isolated 
from Sarcoidosis patients was compared with healthy controls. We report 
down-regulation of pathways related to the mitochondrial respiration system, 
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which could lead to an imbalance in the oxidative homeostasis, in turn 
triggering ROS formation in sarcoidosis patients. This down-regulation was 
true only for non-Löfgren patients and this could in part explain their 
unresolved inflammation and prolonged disease course. The up-regulation of 
pathways related to pyruvate metabolism may be due to the cells trying to 
protect themselves from the increased ROS formation. We also observed up-
regulation in phagocytosis-related pathways in sarcoidosis, which could be 
pathogen-mediated mechanisms of the alveolar macrophages. 
2.4.1 Future perspectives 
Even though gel-based methods have been introduced that are able to resolve 
membrane proteins, they lag behind shotgun methods in the number of identified 
proteins by a factor of at least 10. The challenge concerning successful identification of 
integral membrane protein using a shotgun approach is clearly the solubilization issue. 
Membrane proteins are predominately made up of hydrophobic domains and these 
domains need to be solubilized but at the same time available for enzymatic cleavage. 
Most peptides identified from membrane proteins come from their soluble domains, 
meaning that large parts of the proteins remain undetected, and by that they become 
even more low-abundant in a tryptic peptide sample. An attractive approach could be to 
first remove the soluble proteins and then target the hydrophobic domains of the 
membrane proteins by using e.g. shaving to get rid of the soluble parts. One could then 
use narrow range IEF in a pH range that is favorable for hydrophobic peptides. 
One of the aims in paper III was to search for plasma membrane bound proteins that 
could differentiate between ACCs and ACAs. A plasma membrane protein could 
possibly become a target for new diagnostic strategies using e.g. PET scanning. Since 
most membrane proteins found with our method belonged to intracellular organelles, 
further enrichment/purification of the membrane fraction is needed in order to reach the 
more low-abundant plasma membrane proteins. Plasma membrane proteins are maybe 
the most interesting protein population among membrane proteins, especially regarding 
cancer which partly is regarded as a disease of aberrant signal processing, and is 
therefore a very interesting future research area.  
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